Gland Pharma Ltd vs Ind Swift Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Gland Pharma Ltd is ₹ 1751 as of 30 Apr 15:30 . The P/E Ratio of Gland Pharma Ltd changed from 40.7 on March 2021 to 37.5 on March 2025 . This represents a CAGR of -1.62% over 5 yearsThe P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.9 on March 2023 to 2.3 on March 2025 . This represents a CAGR of -30.66% over 3 years The Market Cap of Gland Pharma Ltd changed from ₹ 40535 crore on March 2021 to ₹ 26232 crore on March 2025 . This represents a CAGR of -8.34% over 5 yearsThe Market Cap of Ind-Swift Laboratories Ltd changed from ₹ 425.72 crore on March 2021 to ₹ 509.08 crore on March 2025 . This represents a CAGR of 3.64% over 5 years The revenue of Gland Pharma Ltd for the Dec '25 is ₹ 1758 crore as compare to the Sep '25 revenue of ₹ 1571 crore. This represent the growth of 11.93% The revenue of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 178.43 crore as compare to the Sep '25 revenue of ₹ 170.5 crore. This represent the growth of 4.65% The ebitda of Gland Pharma Ltd for the Dec '25 is ₹ 473.7 crore as compare to the Sep '25 ebitda of ₹ 398.05 crore. This represent the growth of 19.01% The ebitda of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 25.9 crore as compare to the Sep '25 ebitda of ₹ 19.34 crore. This represent the growth of 33.92% The net profit of Gland Pharma Ltd changed from ₹ 143.76 crore to ₹ 261.48 crore over 7 quarters. This represents a CAGR of 40.75% The net profit of Ind-Swift Laboratories Ltd changed from ₹ 1.01 crore to ₹ 9.52 crore over 7 quarters. This represents a CAGR of 260.37% The Dividend Payout of Gland Pharma Ltd changed from 31.57 % on March 2024 to 27.22 % on March 2025 . This represents a CAGR of -7.14% over 2 yearsThe Dividend Payout of Ind-Swift Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Gland Pharma Ltd

Gland Pharma Limited was incorporated as Gland Pharma Private Limited', a private limited company on March 20, 1978 and was granted the certificate of incorporation by Registrar of Companies, Andhra Pradesh at Hyderabad.
Subsequently, the name of the Company was changed to Gland Pharma Limited' and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad.
The Company is primarily engaged in manufacturing injectable formulations. Established in Hyderabad, India, Company has evolved into a prominent entity in the global generic injectables market, with operations extending to over 60 countries including the United States, Europe, Canada, Australia, and India.
Primarily functioning under a B2B model, the company provides comprehensive services such as contract development, dossier compilation, technology transfer, and manufacturing across various delivery systems.

About Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, Punjab, India.
The Company is one of the leading manufacturers of APIs catering to global and domestic formulators.
Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards.
Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide. Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

FAQs for the comparison of Gland Pharma Ltd and Ind-Swift Laboratories Ltd

Which company has a larger market capitalization, Gland Pharma Ltd or Ind-Swift Laboratories Ltd?

Market cap of Gland Pharma Ltd is 28,848 Cr while Market cap of Ind-Swift Laboratories Ltd is 1,190 Cr

What are the key factors driving the stock performance of Gland Pharma Ltd and Ind-Swift Laboratories Ltd?

The stock performance of Gland Pharma Ltd and Ind-Swift Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gland Pharma Ltd and Ind-Swift Laboratories Ltd?

As of May 3, 2026, the Gland Pharma Ltd stock price is INR ₹1751.0. On the other hand, Ind-Swift Laboratories Ltd stock price is INR ₹137.15.

How do dividend payouts of Gland Pharma Ltd and Ind-Swift Laboratories Ltd compare?

To compare the dividend payouts of Gland Pharma Ltd and Ind-Swift Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.